- search hit 1 of 1
Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib‐resistant non‐nodal leukemic mantle cell lymphoma
Please always quote using this URN: urn:nbn:de:bvb:20-opus-215513
- We herein report the case of a 73‐year‐old male patient who was diagnosed with leukemic non‐nodal MCL. This patient had received six cycles of bendamustine, which resulted in a transient remission, and a second‐line therapy with ibrutinib, which unfortunately failed to induce remission. We started a treatment with single‐agent obinutuzumab at a dose of 20 mg on day 1, 50 mg on day 2‐4, 330 mg on day 5, and 1000 mg on day 6. The laboratory analysis showed a rapid decrease of leukocyte count. Four weeks later, we repeated the treatment withWe herein report the case of a 73‐year‐old male patient who was diagnosed with leukemic non‐nodal MCL. This patient had received six cycles of bendamustine, which resulted in a transient remission, and a second‐line therapy with ibrutinib, which unfortunately failed to induce remission. We started a treatment with single‐agent obinutuzumab at a dose of 20 mg on day 1, 50 mg on day 2‐4, 330 mg on day 5, and 1000 mg on day 6. The laboratory analysis showed a rapid decrease of leukocyte count. Four weeks later, we repeated the treatment with obinutuzumab at a dose of 1000 mg q4w and started a therapy with venetoclax at a dose of 400 mg qd, which could be increased to 800 mg qd from the third cycle. This combination therapy was well tolerated. The patient achieved a complete remission (CR) after three cycles of obinutuzumab and venetoclax. To date, the patient has a progression‐free survival of 17 months under ongoing obinutuzumab maintenance q4w. This is the first report about obinutuzumab and venetoclax induced CR in rituximab‐intolerant patient with an ibrutinib‐resistant MCL. This case suggests that obinutuzumab‐ and venetoclax‐based combination therapy might be salvage therapy in patients with ibrutinib‐resistant MCL.…
Author: | Xiang ZhouORCiD, Maximilian Johannes Steinhardt, Johannes Düll, Franziska Krummenast, Sophia Danhof, Katharina Meckel, Katharina Nickel, Denise Grathwohl, Hans‐Benno Leicht, Andreas Rosenwald, Hermann Einsele, Leo Rasche, Martin Kortüm |
---|---|
URN: | urn:nbn:de:bvb:20-opus-215513 |
Document Type: | Journal article |
Faculties: | Medizinische Fakultät / Pathologisches Institut |
Medizinische Fakultät / Medizinische Klinik und Poliklinik II | |
Language: | English |
Parent Title (English): | European Journal of Haematology |
Year of Completion: | 2020 |
Volume: | 104 |
Issue: | 4 |
First Page: | 352 |
Last Page: | 355 |
Source: | European Journal of Haematology 2020, 104(4):352–355. DOI: 10.1111/ejh.13382 |
DOI: | https://doi.org/10.1111/ejh.13382 |
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Tag: | mantle cell lymphoma; obinutuzumab; venetoclax |
Release Date: | 2021/07/01 |
Licence (German): | CC BY-NC: Creative-Commons-Lizenz: Namensnennung, Nicht kommerziell 4.0 International |